Thank you, Mr. Chair.
Thank you to all the witnesses for being with us.
My question is for Ms. Steele from the Best Medicines Coalition.
Ms. Steele, you highlighted the leadership of the provinces and the bilateral agreement, but where is the biggest barrier in Canada's drug review and health technology assessment processes, and what reforms would you recommend to make these processes more timely?